MSANTD3-TMEFF1 readthrough (MSANTD3-TMEFF1)

MSANTD3-TMEFF1 readthrough represents a naturally occurring read-through transcriptional fusion between the adjacent MSANTD3 (Myb/SANT-like DNA-binding domain containing 3) and TMEFF1 (transmembrane protein with EGF-like and two follistatin-like domains 1) genes[1][2][6]. This produces a fusion protein sharing sequence identity with both individual gene products. There is limited characterization of its function or role as a drug target. Functional annotations suggest receptor ligand inhibitor activity and involvement in host-mediated suppression of symbiont invasion[3], but there is no evidence supporting its use as a direct therapeutic target. It has been linked to certain neurological conditions such as frontotemporal dementia and/or ALS[1]. Notes: - This is a transcriptional fusion/locus, not a conventional receptor, enzyme, or transporter. - There is no strong evidence that MSANTD3-TMEFF1 readthrough functions as a therapeutic target, and it is not traditionally recognized as such in pharmacological reference resources. - Its "receptor ligand inhibitor activity" annotation is based on predicted or inferred function, not validated target biology. - The term is correct as a gene symbol, but not as a standard therapeutic target; it is better classified as a "readthrough fusion transcript" than a receptor or other canonical drug target. - Alias "C9orf30-TMEFF1" reflects an older gene naming convention[1].

Other names

C9orf30-TMEFF1